Lead Product(s) : Atumelnant
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Crinetics Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and t...
Product Name : CRN04894
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Atumelnant
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Crinetics Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa Announces Health Canada Approval for Phase 2a Tolimidone in Type 1 Diabetes
Details : MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase which increases phosphorylation of insulin substrate 1, being developed for the treatment of type 1 diabetes.
Product Name : MLR-1023
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2024
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
At278 Insulin Shows Superiority in Phase I Trial for Type 2 Diabetes
Details : AT278 is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection. It is being evaluated for the treatment of type 2 diabetics.
Product Name : AT278
Product Type : Hormone
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Ladenburg Thalmann & Co
Deal Size : $6.0 million
Deal Type : Public Offering
Details : The net proceeds will be used to advance the development of MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase which increases phosphorylation of insulin substrate 1, being developed for the treatment of type 1 diabetes.
Product Name : MLR-1023
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 21, 2023
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Ladenburg Thalmann & Co
Deal Size : $6.0 million
Deal Type : Public Offering
Lead Product(s) : ZB-168
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : JATT Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp
Details : The combined company will focus on the clinical development of pipeline candidates ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways.
Product Name : ZB-168
Product Type : Antibody
Upfront Cash : Undisclosed
March 21, 2023
Lead Product(s) : ZB-168
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : JATT Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AT278, is an ultra-concentrated novel formulation of insulin, that has been designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insuli...
Product Name : AT278
Product Type : Hormone
Upfront Cash : Inapplicable
December 04, 2022
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ultra Rapid Acting Insulin Aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AT247 (ultra rapid acting prandial insulin aspart) has the potential to significantly improve blood glucose control when delivered via insulin pump and is an important step in enabling the development of a fully closed loop/artificial pancreas system for...
Product Name : AT247
Product Type : Peptide
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Ultra Rapid Acting Insulin Aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from Phase I clinical trial of AT278 (Ultra-Concentrated Rapid Acting Insulin Aspart), showed that it exhibited an accelerated PK and PD profile when compared to NovoRapid®, a gold standard prandial insulin treatment, despite a 5-fold increase in c...
Product Name : AT278
Product Type : Hormone
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PK/PD profile for AT278 was accelerated compared with NovoRapid. Following dosing, AT278 showed faster onset of insulin exposure compared with NovoRapid, demonstrated by an earlier onset of appearance, also showed rapid onset of glucose-lowering effect c...
Product Name : AT278
Product Type : Hormone
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ultra Rapid Acting Insulin Aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products
Details : AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes.
Product Name : AT247
Product Type : Peptide
Upfront Cash : Inapplicable
March 23, 2022
Lead Product(s) : Ultra Rapid Acting Insulin Aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable